← All trials
NCT03412643
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2018
- Primary completion
- Oct 30, 2023
- Completion date
- Oct 30, 2023
- First posted
- Jan 26, 2018
- Last posted
- Mar 6, 2023
- Enrollment
- 64
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NSABP FoundationLead sponsor
- GenentechCollaborator
- NSABP FoundationOverall official - principal investigator
- NSABP FoundationOfficial
- CelcuityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.